-
News Summary
Wednesday, June 22, 2011 - 9:39am | 217Shares of FedEx Corp (NYSE: FDX) rose about 3% after the company reported a 33% rise in its fiscal fourth-quarter profit. FedEx reported its quarterly profit at $558 million, or $1.75 per share, up from $419 million, or $1.33 per share, in the year-earlier period. Its total revenue climbed 12% to $...
-
Allergan Reports New Study Finds That Gastric Banding Pays For Itself In Approximately Two Years For Patients With Diabetes And Four Years For Patients Without Diabetes
Wednesday, June 22, 2011 - 9:05am | 257Allergan, Inc. (NYSE: AGN) today announced a new study published in the peer-reviewed journal Surgery for Obesity and Related Diseases that found the cost of a gastric banding weight-loss surgery procedure, such as Allergan's LAP-BAND® Adjustable Gastric Banding System, was offset by reductions in...
-
Bank of America Merrill Lynch Maintains Buy on Pfizer
Wednesday, June 22, 2011 - 8:26am | 99Bank of America Merrill Lynch is out with its report today on Pfizer (NYSE: PFE), maintaining Buy. In a note to clients, Bank of America Merrill Lynch writes, "Pfizer offers compelling valuation, an attractive dividend yield, and the potential for the ongoing strategic review to lead to actions...
-
News Summary for June 22, 2011
Wednesday, June 22, 2011 - 8:00am | 385This is your Benzinga news summary and traders' outlook for Wednesday, June 22, 2011, covering headlines from overnight and Wednesday's pre-market session. Today in domestic pre-market trading, U.S. equity futures are trading lower as the U.S. dollar is slightly higher this morning as investors...
-
Discovery Labs' Proprietary Aerosol Drug Delivery Technology Showcased at the International Society for Aerosols in Medicine Annual Meeting
Wednesday, June 22, 2011 - 7:04am | 280Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that scientific data relating to the Company's proprietary aerosolization technology platform was presented at the 2011 International Society for Aerosols in Medicine (ISAM) Annual Meeting. The annual ISAM congress brings together experts...
-
VIVUS Announces Multiple Presentations Featuring Long-term QNEXA Data at the American Diabetes Association 71st Scientific Sessions
Wednesday, June 22, 2011 - 7:00am | 174VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts have been accepted for presentation at the upcoming American Diabetes Association meeting to be held June 24th to June 28th, 2011, at the San Diego Convention Center, San Diego, CA. Timothy Garvey, MD, Professor of Medicine and...
-
US Stock Futures Down, Fed In Focus
Wednesday, June 22, 2011 - 6:17am | 531US stock futures are lower this morning, as investors are awaiting the latest interest-rate decision from the Federal Reserve. The Greek government won a key confidence vote late Tuesday. Futures on the Dow Jones Industrial Average dipped 24 points to 12,064.00 and futures on the S&P 500 stock...
-
AstraZeneca To Sell Astra Tech Unit To Dentsply For $1.8B
Wednesday, June 22, 2011 - 2:45am | 66AstraZeneca PLC (NYSE: AZN) announced its plans to sell its Astra Tech dental and healthcare division to Dentsply International Inc for about $1.8 billion in cash. The sale is likely to close in the second half of 2011. AZN shares dropped 0.24% to $49.05 in after-hours trading. Read more from...
-
"Aera!" 06-21-2011
Tuesday, June 21, 2011 - 6:18pm | 887Cusick's Corner All quiet on the western front and that is how the After Hours market finished up with market players waiting on the Greek vote and the FOMC statement tomorrow. The scope of this latest two-day run has been solid but the volume has been low and sentiment, which was previously very...
-
Labopharm Announces Intention To Delist From Nasdaq
Tuesday, June 21, 2011 - 5:05pm | 117Labopharm Inc. (NASDAQ: DDSS) announced today its intention to delist its common shares from The Nasdaq Global Market as of the close of business on June 30, 2011. The Company's common shares will continue to be listed on the Toronto Stock Exchange. Following its delisting from Nasdaq, the Company...
-
Obagi Medical Products Introduces New Clinical Data Showing Combination of Hydroquinone Skin Care System and Tretinoin May Reduce Melasma Severity
Tuesday, June 21, 2011 - 4:15pm | 166Obagi Medical Products, Inc. (Nasdaq: OMPI) announced the results from a new clinical study evaluating the efficacy of a hydroquinone skin care system (Nu-Derm®), plus tretinoin, in decreasing the severity of melasma, particularly in skin of color patients. This data was presented at the 22nd World...
-
Amarin Bounces Back; Up 4.5%
Tuesday, June 21, 2011 - 1:12pm | 82Shares of biotechnology company Amarin (NASDAQ: AMRN) are bouncing back on Tuesday, rising 4.47% to $14.25. The stock has been hit hard over the last month, falling almost 23%. Over the last 52-weeks, however, Amarin shares are up 455%. Amarin Corporation plc (Amarin) is a clinical-stage...
-
Tuesday's Put/Call Ratio Leaders
Tuesday, June 21, 2011 - 12:33pm | 71Here are today's Put/Call Ratio leaders… 1. IntraLinks Holdings (NYSE: IL) 10,041 puts, 28 calls 2. Overseas Shipholding Group (NYSE: OSG) 3,156 puts, 203 calls 3. Cardinal Health (NYSE: CAH) 3,558 puts, 286 calls 4. Spectrum Pharmaceuticals (NASDAQ: SPPI) 2,580 puts, 239 calls 5. Dollar Thrifty...
-
Options Brief: Salix Pharmaceuticals, Ltd.
Tuesday, June 21, 2011 - 10:13am | 84Shares of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) are higher on the session by 1.17%, trading at $37.12. Overall call volume is now running at 19.35x the daily average, with 0% of all calls traded being purchases on the offer. 1,045 contracts have traded on the session so far. Salix...
-
Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases
Tuesday, June 21, 2011 - 9:22am | 132Abbott (NYSE: ABT) and Biotest AG today announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis and psoriasis. BT-061 is currently in Phase II clinical trials for RA and psoriasis, with preclinical studies underway to...